525587-00-2

Usage

Uses

Used in Pharmaceutical Industry:
(2-OXO-2-PIPERAZIN-1-YL-ETHYL)-CARBAMIC ACID TERT-BUTYL ESTER is used as an intermediate in the synthesis of various pharmaceuticals. Its presence in the molecular structure allows for the development of compounds with potential therapeutic applications.
Used in Agrochemical Industry:
(2-OXO-2-PIPERAZIN-1-YL-ETHYL)-CARBAMIC ACID TERT-BUTYL ESTER is also used as an intermediate in the production of agrochemicals, contributing to the development of new pesticides or other agricultural products.
Used in Chemical Research and Development:
As a reagent, (2-OXO-2-PIPERAZIN-1-YL-ETHYL)-CARBAMIC ACID TERT-BUTYL ESTER is utilized in various chemical research and development processes. Its unique structure and properties make it a valuable tool for scientists working on new chemical compounds and reactions.
Used in Medicinal Chemistry:
Due to the presence of the piperazine moiety, (2-OXO-2-PIPERAZIN-1-YL-ETHYL)-CARBAMIC ACID TERT-BUTYL ESTER may have potential applications in medicinal chemistry. The piperazine ring is a common structural element in many pharmacologically active compounds, suggesting that this ester could be a key component in the development of new drugs.

InChI:InChI=1/C11H21N3O3/c1-11(2,3)17-10(16)13-8-9(15)14-6-4-12-5-7-14/h12H,4-8H2,1-3H3,(H,13,16)

Upstream product

• 110-85-0 piperazine 
• 4530-20-5 BOC-glycine 
• 31166-44-6 phenylmethyl 1-piperazinecarboxylate 
• 671212-34-3 [2-(4-benzyl-piperazin-1-yl)-2-oxo-ethyl]-carbamic acid tert-butyl ester 

Downstream Products

• 671212-41-2 {2-[4-(4-fluoro-benzenesulfonyl)-piperazin-1-yl]-2-oxo-ethyl}-carbamic acid tert-butyl ester 
• 671212-25-2 2-amino-1-[4-(4-fluoro-benzenesulfonyl)-piperazin-1-yl]-ethanone 
• 671212-20-7 2-amino-1-(4-benzoyl-piperazin-1-yl)-ethanone 
• 671212-38-7 [2-(4-benzoyl-piperazin-1-yl)-2-oxo-ethyl]-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

EDARAVONE PRODRUG COMPOUND AND PHARMACEUTICAL USE THEREOF IN TREATMENT OR ALLEVIATION OF NEURODEGENERATIVE OR MOTOR NEURON DISEASE

The present invention provides a novel prodrug of an edaravone compound or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising same as an active ingredient, and a use thereof in treatment or alleviation of neurodegenerative and/or motor neuron disease.

4-BENZIMIDAZ0LYL-6-M0RPH0LIN0-2-PIPERAZINYLPYRIMIDINE DERIVATIVES AS P13K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS

The invention concerns pyrimidine derivatives of Formula (I) wherein each of p, R1, R2, q, R3, r, R4, X1 and Q1 have any of the meanings defined in the description; processes for

4-BENZIMIDAZOLYL-2-MORPHOLINO-6-PIPERAZINYLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS

The invention concerns pyrimidine derivatives of Formula (I): wherein each of p, R1, R2, q, R3, r, R4, X1 and Q1 have any of the meanings defined in the description; processes for their pre

PYRIMIDINE DERIVATIVES

The invention concerns pyrimidine derivatives of Formula (I) wherein each of p, R1, R2, q, R3, r, R4, X1 and Q1 have any of the meanings defined in the description; processes for their prep

NOVEL COMPOUNDS

This invention relates to novel compounds useful in the treatment of diseases associated with TRPV4 channel receptor. More specifically, this invention relates to certain substituted piperazines, according to Formula (I). A compound of formula (I) wherein Z is bond or NH; R1 is aryl or optionally substituted heteroaryl; R2 is H, optionally substituted C1-6alkyl, or optionally substituted C2-6alkenyl; R3 and R7 are independently H, optionally substituted C1-6alkyl, or aryl; R4 is H or optionally substituted C1-6alkyl; R5 is H or C1-6alkyl; R6 is H or C1-6alkyl; and X and X' are independently O or H2; or wherein R3 and R4 together form a part of morpholinyl, piperadinyl, or aziridinyl ring; and pharmaceutically acceptable salts thereof.

Structure-activity relationship studies on unifiram (DM232) and sunifiram (DM235), two novel and potent cognition enhancing drugs

Structure-activity relationships on two novel potent cognition enhancing drugs, unifiram (DM232, 1) and sunifiram (DM235, 2), are reported. Although none of the compounds synthesised reached the potency of the parent drugs, some fairly active compounds have been identified that may represent new leads to develop other cognition enhancing drugs. An interesting result of this research is the identification of two compounds (13 and 14) that are endowed with amnesing activity (the opposite of the activity of the original molecules) and are nearly equipotent to scopolamine. Moreover, two compounds of the series (5 and 6) were found endowed with analgesic activity on a rat model of neuropathic pain at the dose of 1 mg/kg.

New Histidyl amino acid derivatives, and pharmaceutical composition comprising the same

A compound of the formula: STR1 wherein R1 is lower alkyl optionally substituted with a substituent selected from the group consisting of acyl, hydroxy, lower alkoxy, aryl, lower alkylthio and a group of the formula: STR2 in which R5 is hydrogen or acyl and R6 is hydrogen or lower alkyl; aryl; or amino optionally substituted with substituent(s) selected from the group consisting of lower alkyl and acyl; and R2 is hydrogen or lower alkyl; or R1 and R2 are taken together with the attached nitrogen atom to form a heterocyclic group optionally substituted with substituent(s) selected from the group consisting of lower alkyl, hydroxy(lower )alkyl, lower alkoxy(lower)alkyl, acyl(lower)alkyl, oxo and acyl; R3 is hydrogen or lower alkyl; and R4 is lower alkyl; and its pharmaceutically acceptable salt, processes for the preparation thereof and pharmaceutical composition comprising the same.